Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon leukemia drug granted orphan status in US
The orphan drug designation will provide a seven-year period of marketing exclusivity for this indication from the date of final FDA marketing approval of the compound. FDA may
The orphan drug designation will provide a seven-year period of marketing exclusivity for this indication from the date of final FDA marketing approval of the compound. FDA may
CVLP vaccines, an abbreviation for chimeric virus-like particles, are based on human papilloma viruses (HPV) which can be a precursor of cervical cancer. MediGene will give Virionics access
The companies anticipate closing the transaction as early as mid-April. Astellas will receive rights to the drug in all indications. Biogen Idec will continue to manufacture the anti-inflammatory
The exclusive worldwide co-development agreement makes QLT responsible for the development and commercialization of products for use in ocular and all other human diseases. Retinagenix will participate in
A phase I clinical trial of TGN1412 was suspended in March after all six trial volunteers taking the drug candidate were hospitalized after suffering serious adverse events. The
Data from a phase III clinical trial in patients with relapsing forms of MS show that the new formulation of Rebif results in a substantial improvement in overall
The action taken by the FDA is related to concerns over some preclinical animal data and not results from any human clinical trials, the company said. “Until Cortex
The product is currently in phase III trials in the US for lung transplantation; however Fresenius currently markets the drug in more than 60 countries worldwide. Nabi will
The study, by Dr Jeffrey Rumbaugh, looked at two proteins, called Tat and gp120, that are part of the virus that causes HIV infection and that are implicated
Amgen recently closed a $2.2 billion deal to acquire its panitumumab development partner, Abgenix. The takeover gives Amgen full control of the anticancer candidate, but the deal will